Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REP 2139-Ca + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Replicor
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
REP 2139-Ca + peginterferon alfa-2a is a combination therapy under investigation for the treatment of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) co-infection. REP 2139-Ca is a nucleic acid polymer (phosphorothioate oligoribonucleotide) that inhibits the release of HBV subviral particles, including hepatitis B surface antigen (HBsAg), thereby enhancing immune control over HBV infection. Peginterferon alfa-2a is a recombinant, long-lasting form of interferon that stimulates antiviral immune responses by binding to type I interferon receptors and activating downstream signaling pathways. The combination has demonstrated potent antiviral effects in phase 2 clinical trials, leading to functional control of both HBV and HDV infections with normalization of liver enzymes in a significant proportion of patients one year after therapy[1][5][6].
- Brand names
- Pegasys
- Other names
- pegylated interferon alfa-2aREP 2139 calcium chelate complexREP2139 calcium chelate complexREP-2139 calcium chelate complex
02
Targets
HBsAg (Hepatitis B surface antigen)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on REP 2139-Ca + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REP 2139-Ca + peginterferon alfa-2a.